XORTX Therapeutics (XRTX) Common Equity (2020 - 2026)
XORTX Therapeutics' (XRTX) quarterly Common Equity came in at $1.3 million in Q1 2026, down 53.17% YoY from $2.7 million in Q1 2025, and down 38.41% on a QoQ basis from $2.1 million in Q4 2025.
XORTX Therapeutics (XRTX) Common Equity (2020 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 7 years of Common Equity data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Common Equity fell 53.17% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 53.17% YoY) and the FY2025 annual result came in at $2.1 million, down 37.53% from the prior year.
- Common Equity eased to $1.3 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $10.6 million in Q1 2022 to a low of $1.3 million in Q1 2026.
- A 5-year average of $4.9 million and a median of $3.3 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity surged 155.01% — and 2024, when it sank 72.5%.
- Tracing XRTX's Common Equity over 5 years: stood at $7.0 million in 2022, then tumbled by 33.44% to $4.6 million in 2023, then slipped by 28.12% to $3.3 million in 2024, then sank by 37.53% to $2.1 million in 2025, then plunged by 38.41% to $1.3 million in 2026.
- The last three Common Equity figures came in at $1.3 million (Q1 2026), $2.1 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - | 1.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.28 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Sep 30, 2025 | 1.97 Mn |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 2.74 Mn |
| Dec 31, 2024 | 3.34 Mn |
| Sep 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 2.70 Mn |
| Mar 31, 2024 | 2.49 Mn |
| Dec 31, 2023 | 4.64 Mn |
| Sep 30, 2023 | 6.09 Mn |
| Jun 30, 2023 | 7.40 Mn |
| Mar 31, 2023 | 9.06 Mn |
| Dec 31, 2022 | 6.97 Mn |
| Sep 30, 2022 | 8.21 Mn |
| Jun 30, 2022 | 9.60 Mn |
| Mar 31, 2022 | 10.58 Mn |
| Dec 31, 2021 | 13.28 Mn |
| Sep 30, 2021 | -14.92 Mn |
| Jun 30, 2021 | 9.97 Mn |